What is the half-life of ceftriaxone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftriaxone Half-Life

The elimination half-life of ceftriaxone in healthy adults ranges from 5.8 to 8.7 hours, with a mean of approximately 6.5 hours. 1

Half-Life by Patient Population

Healthy Adults

  • The FDA label specifies that over a 0.15 to 3 gram dose range in healthy adult subjects, elimination half-life values ranged from 5.8 to 8.7 hours 1
  • This extended half-life is what enables once-daily dosing for most infections 2, 3

Pediatric Patients

  • In pediatric patients with bacterial meningitis, the elimination half-life is shorter at 4.3 to 4.6 hours 1
  • This shorter half-life in children is due to a threefold greater volume of distribution and plasma clearance compared to adults 4

Elderly Patients

  • In elderly subjects (mean age 70.5 years), the half-life is slightly prolonged to 8.9 hours 1
  • Despite this modest increase, no dosage adjustment is necessary for elderly patients receiving up to 2 grams per day 1

Renal Impairment

  • The half-life is significantly prolonged in patients with renal dysfunction: 1

    • Mild impairment (CrCl 31-60 mL/min): 12.4 hours
    • Moderate impairment (CrCl 16-30 mL/min): 11.4 hours
    • Severe impairment (CrCl 5-15 mL/min): 15.7 hours
    • Hemodialysis patients (CrCl 0-5 mL/min): 14.7 hours
  • Critically ill patients with renal failure demonstrate even more prolonged elimination (21.4 ± 9.8 hours) compared to non-critically ill patients with similar renal function 5

  • Ceftriaxone does not require dose adjustment in renal impairment for dosages up to 2 grams per day, as it has dual elimination (renal and biliary) 6, 1

Hepatic Dysfunction

  • In patients with liver disease, the half-life is 8.8 hours, which is only minimally different from healthy subjects 1
  • No dosage adjustment is necessary for hepatic dysfunction alone 1

Special Pharmacokinetic Considerations

Middle Ear Fluid

  • In middle ear fluid of pediatric patients with otitis media, ceftriaxone demonstrates a remarkably prolonged half-life of 25 hours 1
  • This extended tissue half-life supports the effectiveness of single-dose therapy for certain infections 1

Critically Ill Patients

  • In critically ill patients with normal renal function, there is increased ceftriaxone clearance (100% higher than normal subjects) and increased volume of distribution (90% higher), but the elimination half-life remains similar at 6.4 ± 1.1 hours 5
  • This altered pharmacokinetic profile can result in suboptimal plasma concentrations with standard once-daily dosing in some critically ill patients 5

Clinical Implications

Dosing Frequency

  • The long half-life allows for once-daily dosing for most infections, which reduces healthcare costs and improves convenience 2, 3, 7
  • For bacterial meningitis, twice-daily dosing (every 12 hours) is required despite the long half-life to ensure adequate CSF concentrations throughout the dosing interval 2

Common Pitfall

  • Do not assume once-daily dosing is appropriate for all critically ill patients—those with augmented renal clearance may require twice-daily dosing or higher doses to maintain therapeutic concentrations 5

References

Guideline

Ceftriaxone Pharmacokinetics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetic profile of ceftriaxone in man.

The American journal of medicine, 1984

Guideline

Vancomycin and Ceftriaxone Use in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.